A Randomized, Double Blind, Placebo Controlled Trial L-carnitine and Piracetam in the Treatment of Weakness, Muscle Fatigue and Muscle Pain in the Postpoliomyelitis Syndrome
A Phase III, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Therapeutic Effect of the Association of L-carnitine and Piracetam as an Adjuvant Therapy in the Treatment of Weakness, Muscle Fatigue and Muscle Pain in the Postpoliomyelitis Syndrome
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
SP
-
São Paulo, SP, Brazil
- UNIFESP
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with Postpoliomyelitis Syndrome diagnosis confirmed over a year;
- Electromyography test compatible with poliomyelitis;
- Preserved ability to swallow medication;
- Oral communication ability preserved;
- Preserved ability to perform pedaling test in at least one lower limb affected by Postpoliomyelitis Syndrome;
- Ability to understand information about the study and to document the decision about participating in the trial by signing the Informed Consent Form.
Exclusion Criteria:
- History of intolerance to L-carnitine or piracetam;
- Treatment with L-carnitine during the past 3 months;
- Treatment with piracetam or any other nootropics pyrrolidone derivatives, during the past three months;
- Anemia (hemoglobin reference range - men 13 to 17 g/dL and women 12 to 15 g/dL);
- High level of glycated hemoglobin (> 7.0%);
- Electrolyte imbalance (hypokalaemia - reference potassium concentration range: 3.5 to 5.6 mmol / L);
- Renal failure (creatinine reference range: 0.70 to 1.50 mg/dL);
- Urinary tract infection;
- Thyroid dysfunction (reference range: free T4: 0.54 to 0.67 mg/dL and TSH reference range: 0.5 to 5.5 μUI/mL) or usual treatment with thyroid hormone supplementation;
- Cardiomyopathy;
- Uncontrolled hypertension;
- Known or suspected autoimmune disease;
- Confirmed pregnancy, or plans to get pregnant during the trial;
- Depression or bipolar affective disorders with moderate to severe episodes within the last twelve months;
- Insulin-dependent diabetes mellitus;
- Treatment with anticoagulant drugs over two weeks (including non-steroidal anti-inflammatory drugs (NSAIDs), warfarin, phenprocoumon, heparin);
- Usual cocaine or alcohol use;
- Any other condition judged by the investigator as a possibility to interfere on the participant's decision to be part of the study or to accomplish investigation procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Placebo PO BID
|
|
Experimental: L-carnitine and piracetam
|
L-carnitine/piracetam (990mg/810mg) PO BID
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Changes in Muscle Weakness
Time Frame: 26 weeks
|
26 weeks
|
|
Changes in fatigue
Time Frame: 26 weeks
|
26 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Changes in muscle pain
Time Frame: 26 weeks
|
26 weeks
|
|
Changes in daytime sleepiness
Time Frame: 26 weeks
|
26 weeks
|
|
Changes in quality of life
Time Frame: 26 weeks
|
26 weeks
|
|
Changes in daily function
Time Frame: 26 weeks
|
26 weeks
|
|
Changes in depressive mood
Time Frame: 26 weeks
|
26 weeks
|
|
Changes in oxidative capacity in skeletal muscle
Time Frame: 26 weeks
|
26 weeks
|
|
Occurrence of adverse events
Time Frame: 26 weeks
|
26 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Acary Souza Bulle Oliveira, MD, PhD, Federal University of São Paulo
Study record dates
Study Major Dates
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Central Nervous System Diseases
- Nervous System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Pain
- Neurologic Manifestations
- Disease
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Musculoskeletal Pain
- Central Nervous System Infections
- Neurodegenerative Diseases
- Neuromuscular Manifestations
- Enterovirus Infections
- Picornaviridae Infections
- Spinal Cord Diseases
- Muscular Disorders, Atrophic
- Myelitis
- Poliomyelitis
- Syndrome
- Myalgia
- Muscle Weakness
- Postpoliomyelitis Syndrome
- Physiological Effects of Drugs
- Neuroprotective Agents
- Protective Agents
- Nootropic Agents
- Piracetam
Other Study ID Numbers
Other Study ID Numbers
- CAR-PIR.11.01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.